CENTENIAL SURGICAL SUTURE LTD. (CSURGSU) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of CENTENIAL SURGICAL SUTURE LTD. ₹138, price ₹102, upside +35.3%, quality 49 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range ₹35.50 – ₹166.00 · fair‑value band ₹111.81 – ₹182.83 · the ₹102.00 price screens below the ₹137.97 fair value. Dashed = 300-day average. As of Oct 3, 2026.
Follow CENTENIAL SURGICAL SUTURE in your weekly email
Every Wednesday you see whether CENTENIAL SURGICAL SUTURE is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Centenial Surgical Suture Limited engages in the development, manufacturing, and supply of surgical sutures and other medical devices in India and internationally.
Show more
Centenial Surgical Suture Limited engages in the development, manufacturing, and supply of surgical sutures and other medical devices in India and internationally. The company offers absorbable sutures, such as natural and synthetic sutures; and non-absorbable sutures comprising needles for cardiovascular surgery, monofilament polyamide atraumatic needle suture combinations, braided silk atraumatic needle suture combinations, monofilament stainless steel wire, and temporary pacemaker electrodes. It also provides female urinary incontinency sets, titanium hemostatic clips for cardiovascular surgery, non-absorbable synthetic knotted surgical meshes, disposable aortic punches for cardiovascular anastomosis, disposable skin stapler maniplers, and cardiovascular vessel knives for cardiovascular surgery. The company was founded in 1995 and is based in Thane, India.
Stock analysis
CENTENIAL SURGICAL SUTURE LTD. (CSURGSU) currently trades at ₹102.00, while our model-based Fair Value estimate is ₹137.97, implying the stock looks roughly 26.1% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ₹154.31 per share, and 5 of the 10 models we run sit above the ₹102.00 price.
Bear case: the Asset-Based group reads lowest at ₹52.43, and 5 of the 10 models stay below the price. Evidence for this calculation is medium.
Scenario range: ₹111.81 (bear) to ₹182.83 (bull), the price of ₹102.00 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
CENTENIAL SURGICAL SUTURE LTD. reported revenue of ₹538M in FY2026 versus ₹444M in FY2022, a compound +4.9%/yr. Reported net income was −₹22.0M in FY2026.
Key figures
Market cap ₹372M (≈ $3.9M) · P/S ratio 0.66 · EPS (TTM) ₹−3.92 · Net margin −4.1% · Return on equity −7.4% · Return on assets (EBIT) 3.6% · Operating margin 8.2% · Revenue (TTM) ₹562M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 11% below its 52-week high and 40% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −37% fair-value upside, at 35%, CSURGSU screens cheaper than that median.
Fair Value models
Bear ₹111.81Fair Value ₹137.97Bull ₹182.83
Price ₹102.00 · Upside +35.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.53/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+0.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.8%
Start year 2021 (pandemic). Over 10 years: +0.5% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.5%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
9.6% (2021) → 2.0% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+4.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +0.1% a year for the price.
Compare CENTENIAL SURGICAL SUTURE LTD. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 191 stocks
Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score49 · Below median
Fair Value upside+35.3% · Top 25%
Profitability
Return on assets0.8% · Bottom 25%
Net margin (TTM)−2.5% · Bottom 25%
Operating margin (TTM)8.2% · Below median
Growth and dividend
Revenue growth18.6% · Top 25%
Balance sheet
Debt / equity0.62× · Highest 25%
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is CENTENIAL SURGICAL SUTURE LTD. (CSURGSU) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of ₹137.97 versus a price of ₹102.00, about +35% upside (undervalued).
What is the fair value of CSURGSU?
Our model-based fair value for CENTENIAL SURGICAL SUTURE LTD. is ₹137.97 (as of Oct 3, 2026), built from audited fundamentals. The current price: ₹102.00.
What is the quality score of CSURGSU?
CENTENIAL SURGICAL SUTURE LTD. has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CENTENIAL SURGICAL SUTURE LTD. (CSURGSU)?
Our model-based price target is the fair value of ₹137.97 (as of Oct 3, 2026) from 11 valuation models. Cautious scenario ₹111.81, optimistic scenario ₹182.83. It is a calculation from audited fundamentals, not an analyst target.
What is the CENTENIAL SURGICAL SUTURE LTD. stock forecast for 2026?
Our models put fair value at ₹137.97, about +35% upside versus a price of ₹102.00 (undervalued). Cautious scenario ₹111.81, optimistic scenario ₹182.83. The calculation is refreshed regularly with new filings.
What is the revenue of CENTENIAL SURGICAL SUTURE LTD. (CSURGSU)?
CENTENIAL SURGICAL SUTURE LTD. reported trailing-twelve-month revenue of about ₹562M (latest available figure, as of Oct 3, 2026).
What growth is priced into CENTENIAL SURGICAL SUTURE LTD. (CSURGSU)?
For today's price to be fair in a discounted-cash-flow model, CENTENIAL SURGICAL SUTURE LTD. would have to grow free cash flow by +4.2 % per year for five years (discount rate 10.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.8 % per year. As of Oct 3, 2026.
What discount rate (WACC) does the fair value of CSURGSU use?
Our models discount CENTENIAL SURGICAL SUTURE LTD. at 10.9 %: a base by market capitalisation (nano), damped by beta 0.23, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For CENTENIAL SURGICAL SUTURE LTD. that is +4.2 % per year a year over ten years, using the same discount rate (10.9 %) and the same formula as our fair value.
How much growth has CENTENIAL SURGICAL SUTURE LTD. (CSURGSU) delivered so far?
Over the past 5 years revenue at CENTENIAL SURGICAL SUTURE LTD. grew +7.8 % a year. The price currently implies +4.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of CENTENIAL SURGICAL SUTURE LTD. (CSURGSU) growing?
The median revenue growth in the sector is +5.2 % a year. That is the yardstick for the growth priced into CENTENIAL SURGICAL SUTURE LTD. (+4.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of CENTENIAL SURGICAL SUTURE LTD. (CSURGSU)?
The free-cash-flow yield on the price is 13.57 %: that much free cash flow CENTENIAL SURGICAL SUTURE LTD. produces per unit of market value. When it exceeds the discount rate of our models (10.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of CENTENIAL SURGICAL SUTURE LTD. (CSURGSU)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CENTENIAL SURGICAL SUTURE LTD. it is ₹137.97 per share (as of Oct 3, 2026), against a price of ₹102.00. It is the blended result of 11 valuation models (cash flow, earnings, asset, dividend).
Is CENTENIAL SURGICAL SUTURE LTD. stock overvalued or undervalued in 2026?
As of Oct 3, 2026, CSURGSU trades below its calculated fair value: price ₹102.00, fair value ₹137.97, a gap of about +35% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CSURGSU?
No. The price is what the market pays today (₹102.00); the fair value is what the company's own numbers justify (₹137.97). For CENTENIAL SURGICAL SUTURE LTD. the two are ₹35.97 per share apart. That gap is exactly why we show both numbers side by side.
How much is CENTENIAL SURGICAL SUTURE LTD. worth?
The market values CENTENIAL SURGICAL SUTURE LTD. at about ₹372M (market capitalisation, as of Oct 3, 2026). Per share that is ₹102.00; our models calculate a fair value of ₹137.97 per share.
What do the bullish and bearish scenarios say about CSURGSU?
Our models span a range for CENTENIAL SURGICAL SUTURE LTD.: cautious scenario ₹111.81, base ₹137.97, optimistic ₹182.83 per share (as of Oct 3, 2026, price ₹102.00). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of CENTENIAL SURGICAL SUTURE LTD. (CSURGSU)?
Balance-sheet figures for CENTENIAL SURGICAL SUTURE LTD. (as of Oct 3, 2026): return on equity −7.4%, debt of 0.62 per unit of equity. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is CSURGSU from its 52-week high?
CENTENIAL SURGICAL SUTURE LTD. trades at ₹102.00, about 11% below its 52-week high of ₹114.15 and 40% above the low of ₹73.04 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹137.97 is for.
Which stocks are comparable to CENTENIAL SURGICAL SUTURE LTD.?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CENTENIAL SURGICAL SUTURE LTD. stock attractive at the current price?
The data as of Oct 3, 2026: price ₹102.00, calculated fair value ₹137.97 (+35%), Quality Score 49/100, from 11 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CSURGSU calculated?
We run CENTENIAL SURGICAL SUTURE LTD. through 11 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹137.97, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. CENTENIAL SURGICAL SUTURE LTD. currently trades 26 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CENTENIAL SURGICAL SUTURE LTD. (CSURGSU)?
The closing price on Oct 1, 2026 was ₹102.00. Our model-based fair value is ₹137.97, about +35% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CENTENIAL SURGICAL SUTURE LTD. right now?
The price is below even our cautious bear case (₹111.81). The market is more pessimistic than our downside scenario. Solid quality (49/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of CENTENIAL SURGICAL SUTURE LTD.
How large is the market capitalisation of CENTENIAL SURGICAL SUTURE LTD. (CSURGSU)?
The market capitalisation of CENTENIAL SURGICAL SUTURE LTD. is ₹372M (≈ $3.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CENTENIAL SURGICAL SUTURE LTD. (CSURGSU)?
The price-to-sales ratio of CENTENIAL SURGICAL SUTURE LTD. is 0.66 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CENTENIAL SURGICAL SUTURE LTD. (CSURGSU)?
Earnings per share at CENTENIAL SURGICAL SUTURE LTD. are ₹−3.92. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of CENTENIAL SURGICAL SUTURE LTD. (CSURGSU)?
The net margin of CENTENIAL SURGICAL SUTURE LTD. is −4.1% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CENTENIAL SURGICAL SUTURE LTD. (CSURGSU)?
The return on equity (ROE) of CENTENIAL SURGICAL SUTURE LTD. is −7.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CENTENIAL SURGICAL SUTURE LTD. (CSURGSU)?
On an EBIT basis the return on assets of CENTENIAL SURGICAL SUTURE LTD. is 3.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CENTENIAL SURGICAL SUTURE LTD. (CSURGSU)?
The operating margin of CENTENIAL SURGICAL SUTURE LTD. is 8.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CENTENIAL SURGICAL SUTURE LTD. (CSURGSU)?
Revenue at CENTENIAL SURGICAL SUTURE LTD. is growing +18.6% versus a year earlier (3y avg +0.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at CENTENIAL SURGICAL SUTURE LTD. (CSURGSU)?
Earnings per share at CENTENIAL SURGICAL SUTURE LTD. are growing −46.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does CENTENIAL SURGICAL SUTURE LTD. (CSURGSU) carry?
The net debt of CENTENIAL SURGICAL SUTURE LTD. is ₹105M (fiscal year 2026, ≈ 2.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch CENTENIAL SURGICAL SUTURE LTD. in the live analysis
One click puts CENTENIAL SURGICAL SUTURE LTD. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
